Global Cord Blood Corporation

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Global Cord Blood Corporation (OTC: CORBF) resulting from allegations that Global Cord may have issued materially misleading business information to the investing public.

If you purchased Global Cord securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Global Cord securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 29, 2022, after market hours, Global Cord issued a press release entitled “Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights” which discussed Global Cord’s planned acquisition of Cellenkos, Inc (“CLNK”) (a biotechnology research and development company which utilizes umbilical cord blood (“CB”) as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products and which has agreements with The University of Texas MD Anderson Cancer Center).

On this news, Global Cord’s stock price fell $0.98 per share, or 28%, to close at $2.45 per share on May 2, 2022, the next trading day.

On May 9, 2022, during market hours, Global Cord announced a major investor in many of Global Cord’s Chinese subsidiaries, Blue Ocean Structure Investment Company Limited (“BVI”), “filed in the Grand Court of the Cayman Islands a notice of petition to wind up in respect of the issuer (the ‘Notice of Petition’). Among other things, the Notice of Petition primarily seeks an order that: (1) the issuer refrain from proceeding with a proposed transaction by which the issuer would acquire Cellenkos, Inc., as described in a Form 6-K filed by the Issuer on April 29, 2022 (the ‘Cellenkos Transaction’); (2) the issuer amend and restate its Memorandum and Articles of Association to eliminate the classification of the Board and to add shareholder protective provisions; and (3) the issuer convene an extraordinary general meeting to propose the removal of the current Board and the appointment of alternative directors proposed by [BVI].”

On this news, Global Cord’s stock price fell $0.22 per share, or 8%, to close at $2.41 per share on May 9, 2022.

公司名称: Global Cord Blood Corporation
股票代号: CORBF
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。